| Name | Title | Contact Details |
|---|
We are a business and technology consulting firm that specializes in IT, Healthcare, Finance and Construction. We vet businesses, products and people to enable our clients to select the best partners for their business endeavors. Whether youre looking to augment your staff to scale new business growth, enhance your physical and cyber security, or solve complex business problems, Talent Scout is here to connect you to the best business solutions.
IVP, a public listed company, was founded in 1929. We started with vegetable oils and later diversified into an array of fields We were originally part of the TATA Group but later got acquired by the Allanas. Today we are an integral part of the Allana Group. We were the first company to manufacture Foundry Chemicals in India in technical collaboration with M/s Ashland Inc way back in 1965 Our manufacturing plants at Tarapur and Bangalore have a combined annual capacity of approximately 50,000 MT per annum catering to the foundry, composites, refractory & insulation industries in India and neighboring countries.
EDGAR COUNTY BANK IS NOW PROSPECT BANK Edgar County Bank opened its doors in 1873 with a single mission: To help people achieve the American Dream. That mission is as true today as it was 144 years ago. Over time, weve grown alongside the Central Illinois community—and thanks to your support, weve expanded beyond Edgar County. Thats why, effective immediately, Edgar County Bank is now Prospect Bank: a name that reflects who we are today, and our plans for the future. We believe in the people of Central Illinois. As Prospect Bank, were not going anywhere. Were going everywhere—and were excited to show you what we can do for you. If you have any questions about our name change or anything related to Prospect Bank, dont hesitate to contact us. https://www.bankprospect.com/
New York City Center is Manhattan’s first performing arts center, established in 1943 with the goal of making theater, dance, and music accessible to all. Located in a distinctive Neo-Moorish building, it has played a significant role in the cultural life of New York City. The center presents a variety of performing arts programming, focusing on dance and musical theater, and hosts notable series such as the Fall for Dance Festival and the Tony-honored Encores! series. The venue features a 2,557-seat mainstage, two smaller theaters, and four studios, allowing for a diverse range of performances. It serves as a home for the Manhattan Theatre Club’s Off-Broadway productions and showcases internationally acclaimed artists and companies. New York City Center is committed to accessibility and inclusivity, engaging audiences across all five boroughs and supporting educational initiatives that reach thousands of students and families each year.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.